Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up.
The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
Female with age greater than or equal to 18 years
Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest two years before inclusion
Participant with no history of cancer
Male
Age less than 18 years old
Refusal to participate or withdrawal of consent
Pregnant and/or breastfeeding women
Parallel
The DM/DIV ScreenCell is the experimental product studied during this research
DeviceThe product is not used directly on the subject, but on a blood sample taken from the participant.
Evolution of the kinetics of CTC during treatment
Evolution of the number of CTC isolated by ScreenCell technology thanks to a blood draw during the therapeutic management of metastatic and infiltrative non-metastatic breast cancer patients. Average number of CTCs measured during the study (D0, W6, W12, W24, W36) with a tolerance of +/- 8 days for the visits
Molecular characterisation of CTC
Analysis of the expression of specific antigens and the presence of informative mutations on CTCs isolated by ScreenCell technology thanks to a blood draw during the therapeutic management of metastatic and infiltrative non-metastatic breast cancer patients during the study (D0, W6, W12, W24, W36)
Click on the lead sponsor to view all of their trials.
ScreenCell
Lead sponsor
AXELYS SANTE
Collaborator
